

[ABSTRACT]

A conjugate having stability improved more than conventional conjugates without impairing the efficacy is provided by the present invention. The conjugate of the
5 present invention is a conjugate of an anti-EGFR antibody site-specifically modified with a peptide and a chelating agent, wherein the chelating agent is chelated with a metal radionuclide, the peptide and the chelating agent are linked by a linker (L), and the linker (L) does not contain a thiourea
10 bond.

Fig. 1